Overview

CBD in Postmenopausal Women With Osteopenia

Status:
Not yet recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.

Phase:

Phase 1

Details

Lead Sponsor:

Canopy Growth Corporation

Collaborator:

NM Clinical Research & Osteoporosis Center, Inc.